By Katherine Hamilton
Shares of Pacira BioSciences slipped after the company's preliminary-revenue report came in below Wall Street estimates.
The stock fell 9.7%, to $23.49, in after-hours trading Thursday. Through the close, the stock was up about 40% over the past 12 months.
The Brisbane, Calif., developer of pain therapies said its preliminary unaudited revenue for 2025 is $726.4 million. That would be below the $729.5 million analysts were forecasting, according to FactSet.
Preliminary sales of Exparel in the fourth quarter were $155.8 million, which would miss the $158.1 million analysts projected.
Volume growth was partially offset by a shift in vial mix and discounting associated with the launch of a new group purchasing organization partnership, Pacira said.
For the full year, Exparel's preliminary sales were $575.1 million, which would miss estimates by about $2 million.
Annual sales projections for Zilretta and Ioveradeg were roughly in line with Wall Street's expectations.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
January 08, 2026 18:10 ET (23:10 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.